Development and Application of Nicotinic Acetylcholine Receptor Targeted Peptides for Biomedical Research
烟碱乙酰胆碱受体靶向肽在生物医学研究中的开发及应用
基本信息
- 批准号:10550213
- 负责人:
- 金额:$ 44.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAnalgesicsAnimal ModelBiomedical ResearchCellsConus genusDevelopmentDiabetes MellitusDiseaseFundingGoalsImmuneLaboratoriesLearningLigandsMammary NeoplasmsMedicineModelingModificationMoodsMovement DisordersNeurogliaNeurotransmittersNicotinic ReceptorsParkinson DiseasePeptidesPharmaceutical PreparationsPropertyRecoveryResearchResourcesRewardsSignal TransductionSiteSkinSnailsSourceSpecificityStructureSystemTestingTherapeuticTissuesTraumaVenomschemotherapygastrointestinal epitheliuminsightinterestmarinenerve injurynovelpainful neuropathypreventprograms
项目摘要
Project Summary/Abstract
Nicotinic acetylcholine receptors (nAChRs) are broadly expressed in the CNS where they modulate the release
of key neurotransmitters involved in learning, mood, and reward. nAChRs are also found in diverse non-
neuronal tissues including immune cells, skin, gastro-intestinal epithelium and breast tumors. Research in our
laboratory, which has been funded by R01 GM103801 and a project of P01 GM48677, is focused on enabling
mechanistic understanding of how nAChRs regulate signaling at the single cell and systems levels. Venoms
from predatory marine snails, known as Conus, are the richest known source of diverse, evolutionarily-refined
ligands that target nAChRs. We have made substantial progress in developing peptides from these venoms
that are selective for α6 subunit-containing subtypes of nAChRs. These peptides have been widely used to
demonstrate that specific nAChR subtypes modulate key dopaminergic circuits that are strongly implicated in
the addictive properties of drugs and in movement disorders such as Parkinson’s disease. Separately, we
made groundbreaking progress in validating the α9α10 nAChR as a novel target for treatment of neuropathic
pain. We enabled such progress by developing potent and highly selective conopeptides. Over the next 5
years, an overarching goal of our research program will be to develop robust suites of potent, highly selective
conopeptide-based probes for the study of additional subtypes of nAChRs. We will continue to exploit the
resulting compounds for applications in medicine. A particular focus will be to develop new ligands with high
specificity for nAChR subtypes of non-neuronal cells. The most widely expressed nAChRs in non-neuronal
cells have α7, α9, α10 and α5 subunits where our insight into function is limited. We will utilize the resulting
peptide probes to examine the structures and functions of these nAChR subtypes. We have demonstrated that
block of α9α10 nAChRs is analgesic in multiple animal models of neuropathic pain. Of high interest to us, is
that selective conopeptides not only alleviate neuropathic pain, but they also prevent development of, or
accelerate recovery from, nerve injury. Thus, the underlying therapeutic mechanism has significant implications
for truly disease-modifying therapies. We will test the hypothesis that modulation of nAChRs in non-neuronal
cells is key to understanding disease modification observed in models of trauma-, chemotherapy- and
diabetes-induced nerve injury.
项目总结/摘要
烟碱型乙酰胆碱受体(nAChR)在CNS中广泛表达,在CNS中它们调节
学习、情绪和奖赏的关键神经递质。nAChR也存在于多种非
神经元组织,包括免疫细胞、皮肤、胃肠上皮和乳腺肿瘤。在我们的研究
该实验室由R 01 GM 103801和P01 GM 48677项目资助,重点是使
nAChRs如何在单细胞和系统水平上调节信号传导的机制理解。毒液
来自肉食性海洋蜗牛,被称为芋螺,是最丰富的已知来源,
靶向nAChRs的配体。我们在从这些毒液中开发肽方面取得了实质性进展
对含有α6亚基的nAChR亚型具有选择性。这些肽已被广泛用于
表明特定的nAChR亚型调节关键的多巴胺能回路,
药物的成瘾性和运动障碍,如帕金森氏病。另外,我们
在验证α9α10 nAChR作为治疗神经病变的新靶点方面取得了突破性进展,
痛苦我们通过开发有效且高度选择性的锥形肽实现了这一进展。在未来5
多年来,我们的研究计划的首要目标将是开发强大的套件,
用于研究nAChR的其他亚型的基于锥肽的探针。我们将继续利用
所得化合物用于医药。一个特别的重点将是开发新的配体与高
对非神经元细胞的nAChR亚型的特异性。在非神经元细胞中最广泛表达的nAChRs
细胞有α7、α9、α10和α5亚基,我们对这些亚基的功能了解有限。我们将利用由此产生的
肽探针来检查这些nAChR亚型的结构和功能。我们已经证明
阻断α9α10 nAChR在多种神经性疼痛动物模型中具有镇痛作用。我们非常感兴趣的是
选择性芋螺肽不仅可以减轻神经性疼痛,而且还可以防止神经性疼痛的发展,
加速神经损伤的恢复因此,潜在的治疗机制具有重要意义
真正的疾病缓解疗法。我们将检验非神经元细胞中nAChRs的调节
细胞是理解在创伤、化疗和
糖尿病引起的神经损伤
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J MICHAEL MCINTOSH其他文献
J MICHAEL MCINTOSH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J MICHAEL MCINTOSH', 18)}}的其他基金
Alpha-Conotoxin - alpha9_alpha10 nAChRs
α-芋螺毒素 - alpha9_alpha10 nAChR
- 批准号:
8145706 - 财政年份:2010
- 资助金额:
$ 44.99万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 44.99万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 44.99万 - 项目类别:














{{item.name}}会员




